AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the European Union (EU) for the treatment of adult patients with previously ...
SUZHOU, China, March 27, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today reported 2024 annual ...
Zacks Small Cap Research on MSN13d
INAB: Introducing INB-600, A γδ T Cell Engager PlatformINAB READ THE FULL INAB RESEARCH REPORT Following the announcement of its new γδ T cell engager platform INB-600, IN8bio, Inc ...
Kurz KS, Steinlein S, Kreuz M, et al. Age- and gender-specific molecular characteristics of diffuse large B-cell lymphoma: Results from clinical trials of the DSHNHL ...
This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. This work is licensed under a Creative Commons Attribution 4.0 International ...
We excluded patients with histologic transformation to diffuse large B-cell lymphoma or other aggressive lymphomas at ... Real-world progression-free survival (Rw-PFS) is defined as the time from ...
Conclusion: First-line treatment with the ZR-CHOP regimen improved CRR in the untreated patients with DE-DLBCL and prolonged PFS in the Ki67 index >75% subgroup and the p53 expression >50% subgroup.
Overall survival data was not yet mature with less than a quarter of the required number of events having occurred. Credit: Shutterstock / Maria Sbytova. Pharma giant Pfizer and Arvinas’s human ...
Additionally, the median PFS was 4.8 months (95% CI ... discussed what the findings from the primary analysis of the ELM-1 trial of odronextamab in DLBCL means for oncologists. Matasar: We have long ...
DLBCL is a cancer of the lymphatic system and the most common and difficult to treat form of large B-cell lymphoma, which is a type of non-Hodgkin lymphoma. Nearly 40% of patients experience ...
Multivariate analysis revealed that serum CA125, cell of origin, IPI score and albumin were independent prognostic factors for OS and PFS. In addition, the results of the immunohistochemistry ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback